CFZ533 for Sicca Syndrome
This study is evaluating whether a drug may help treat Sjögren's syndrome.
See full descriptionAbout the trial for Sicca Syndrome
Treatment Groups
This trial involves 8 different treatments. CFZ533 is the primary treatment being studied. Participants will be divided into 6 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for CFZ533 + TAC + MMF (Part 1)
Eligibility
This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether CFZ533 will improve 2 primary outcomes and 9 secondary outcomes in patients with Sicca Syndrome. Measurement will happen over the course of 24 weeks.
Patient Q & A Section
What are the signs of sicca syndrome?
A skin condition or dry eye syndrome should be part of the diagnosis of Sjogren Syndrome (SS), however most patients do not develop dry eye symptoms. Dysautonomia is common in patients with SS, but is far more common in patients with primary Sjögren’s Syndrome (PGS). Dysautonomia in SS is associated with increased eye discomfort and the presence of dry eyes and tears. There are two forms of dry eye; the chronic form, which presents with corneal dryness and decreased tear production. The acute form is characterised by swelling of the ocular tissues and ocular secretion abnormalities. Drowsing may be a sign of dry eye syndrome, but this is rare in PGS.
What are common treatments for sicca syndrome?
The skin is often dry, the eyes dryish and hair brittle. The use of lubricants is often helpful. Sudden weight loss in a child is sometimes a problem and can often be corrected with increased caloric intake.\n
What causes sicca syndrome?
Despite the lack of consensus on etiology, this information could be useful as an aid to in-depth patient evaluation to identify cause and improve future treatments.
Can sicca syndrome be cured?
As sicca syndrome is a relatively rare disease, its clinical features and treatment regimens are very diverse. Despite that, patients with sicca syndrome often have symptoms that are improved with treatment.
What is sicca syndrome?
Sicca syndrome is a clinical diagnosis. It is characterized in many patients by dry eyes or dry mouth and by severe xerostomia or xerophthalmia, frequently associated with impaired visual acuity. The presence of these symptoms is helpful in identifying patients who may profit from sertraline treatment in a clinical trial.
How many people get sicca syndrome a year in the United States?
In the United states, there is an estimated 3.2 million Americans diagnosed with dry eye syndrome. Although no prevalence estimate exists for sicca syndrome, it is estimated that 1 in 4 Americans is a sicca syndrome sufferer.
How does cfz533 work?
Taken together, our findings do not support a mechanism by which Cfz533 exerts its effects in Sjögren-löfgren syndrome. That Sjögren-löfgren syndrome arises from a defect or loss of function in one of the IF Nf-KB signaling components, we propose, indicates that Csfz533 is a new member of a unique class of therapeutic agents in Sjøgren-Löfgren syndrome: IF NF-KB inhibitors.
Have there been any new discoveries for treating sicca syndrome?
There has not yet been a big discovery for the treatment of the sicca symptoms. There is only a new method that has the ability to give the patient a longer life while they get rid of the symptoms of the disorder. The method is that of noninvasive laser or laser medicine. For this method, patients needs an additional medical and skin examination process to make sure their patient has no irregularities or medical conditions that may interfere with the treatment that is performed.
Have there been other clinical trials involving cfz533?
This is the first study to provide the convincing evidence that cfz533 is effective against Sjögren's syndrome, a chronic autoimmune inflammatory disorder that primarily affects peripheral joints and the glandular mucosa. Sjögren's syndrome has an unusually poor prognosis, with a reported 5-year survival rate of only 30%. There are currently no known anti-Sjögren's agents available at the time of this publication (2012). Treatment options are limited and focused on palliative care, such as symptomatic treatments, pain relief or palliative surgery.
What is the latest research for sicca syndrome?
[Today, there is no single known cause, but there are several commonalities between primary Sjögren's syndrome and the condition (SS) described in this article(https://healthpages.ncbi.nlm.nih.gov/conditions/primary-sicca-syndrome). Most patients with SS also have a systemic autoimmune disease, termed a connective tissue disorder (CTD), as is also often the case in autoimmune polyendocrine syndrome, type 1. In a report on the epidemiology of sicca syndrome, we discuss a possible role for both immunogenic (e.g., CTD) genetic variants and autoimmune-diarrheal diseases as risk factors for the development of SS.
What is cfz533?
For the first time, we have identified a novel heterogeneous autosomal recessive skin disorder associated with chronic progressive dry skin and chronic inflammatory disease in children. Here, we also describe, report, and classify the genetic origin of the disease.
How serious can sicca syndrome be?
For patients under the age of 50 [sicca syndrome is the 3rd most common cause of dry lips and dry mouth after [alcoholics' dry lips and oral mucosa] and [dermatologic diseases of the skin and hair]]]. It often causes people to stop communicating, and may also lead to a less healthy diet as people become reluctant to eat. More women have moderate to severe sicca than men, and more than 1/3 of people with sicca have dry lips, dry mouth and dry eyes, and 2/3 have itching.